Why Structured Due Diligence Should Precede Any UK or EU Filing
For US sterile injectable companies holding FDA-approved ANDAs, international expansion often begins with a practical question:
“What would it take to file this product in the UK or EU?”
That question is reasonable — but incomplete.
A more valuable starting point for senior management is:
“Should we file at all, and under what conditions?”
The distinction matters. Filing is an operational step. Due diligence is a strategic one.
Due diligence is not regulatory paperwork — it is risk control
When companies move directly from interest to execution, they typically focus on:
Identifying the regulatory pathway
Mapping submission requirements
Estimating timelines to approval
All of which are necessary.
What is often missing is a structured, integrated assessment of:
The extent to which the existing ANDA data package is genuinely portable
Where regulatory interpretation risk may sit
Whether additional data generation is likely
The true manufacturing and tech transfer implications
How these factors affect cost, timing, and commercial viability
Without this assessment, filing decisions are made on partial information
The cost of filing before clarity
When programmes encounter difficulty, it is rarely because the science fails. More often, it is because assumptions were not stress-tested early.
Late-stage regulatory questions can lead to:
Additional data commitments
Extended review cycles
Unplanned manufacturing adjustments
Margin erosion
These are not catastrophic failures — but they are expensive and distracting.
For sterile injectables, where operational discipline and supply reliability are critical, the cumulative effect can materially affect the business case.
A structured due diligence phase exists to prevent precisely this kind of drift.
What structured due diligence should deliver
An effective assessment does more than confirm that a pathway exists. It should provide senior management with:
A clear statement of regulatory feasibility
Identification of likely areas of scrutiny
A defined scope of any additional work required
A fully costed execution plan
An integrated view of regulatory, technical, and commercial risk
Equally important, it should provide the confidence to decide not to proceed if the case does not hold.
Clarity is the objective — not momentum.
The discipline of deciding early
One of the most valuable outcomes of structured due diligence is the ability to preserve optionality.
Before filings begin, before manufacturing changes are locked in, before supply chains are adjusted, management retains flexibility.
After those commitments are made, flexibility reduces rapidly.
This is why the most effective international expansions I observe begin with a deliberate pause. Not to delay progress, but to ensure that progress is grounded in evidence.
Conclusion
An FDA-approved ANDA is a strong foundation. But UK and EU market entry is not an automatic extension of that approval.
Structured due diligence should precede any filing decision because it transforms a regulatory exercise into a managed commercial strategy.
For senior leadership, that distinction is not academic. It is the difference between expansion that creates value — and expansion that consumes it.